United States · Bill · HR
H.R. 6963 (117th)
Accelerated Approval Integrity Act of 2022
Introduced
7 March 2022
Last action
—
Status
Referred to the Subcommittee on Health.
Sponsors
—
Subjects
Discovery layer
Source updated
7 April 2025
Summary
Accelerated Approval Integrity Act of 2022 This bill establishes requirements relating to postapproval studies for drugs that receive accelerated approval for serious or life-threatening diseases or conditions, such as requiring product sponsors to agree in advance to conduct such studies and terminating product approval if certain benchmarks are not met.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
3 official files
Introduced in House (text)
Introduced in House (text)
Introduced in House · EN · 7 March 2022
Introduced in House (PDF)
Introduced in House · EN · 7 March 2022
Introduced in House
summary · EN · 7 March 2022
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/117th-congress/house-bill/6963
- Open data entity: https://api.congress.gov/v3/bill/117/hr/6963